Global Bioreactor Market

1 INTRODUCTION OF GLOBAL BIOREACTORMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BIOREACTORMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL BIOREACTOR MARKET, BY CELL:
5.1 Mammalian Cells
5.2 Bacterial Cells
5.3 Yeast Cells
5.4 Others

6 GLOBAL BIOREACTOR MARKET, BY MOLECULE:
6.1 Monoclonal Antibodies
6.2 Vaccines
6.3 Recombinant Proteins
6.4 Stem Cells
6.5 Gene Therapy
6.6 Others

7 GLOBAL BIOREACTOR MARKET, BY TECHNOLOGY:
7.1 Wave-Induced Motion SUB
7.2 Stirred SUB
7.3 Single Use Bubble Column
7.4 Other SUB

8 GLOBAL BIOREACTOR MARKET, BY END USER:
8.1 R&D organizations
8.2 Biopharma
8.3 Manufacturers
8.4 CMOs

9 GLOBAL BIOREACTORMARKET, BY GEOGRAPHY
9.1 Overview
9.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

10 GLOBAL BIOREACTORMARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES
11.1 Thermo Fisher Scientific
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments

11.2 PBS Biotech
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments

11.3 GE Healthcare
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments

11.4 Merck Group
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments

11.5 Cellexus Ltd
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments

11.6 Pall Corporation
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments

11.7 Sartorius Stedium Biotech Group
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments

11.8 Applikon Biotechnology, Inc.
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments

11.9 GEA Group Aktiengesellschaft
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Development

11.10 BioTron Inc.
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Development

11.11 Bbi Biotech
11.11.1 Overview
11.11.2 Financial Performance
11.11.3 Product Outlook
11.11.4 Key Development

11.12 Bailun Bio
11.12.1 Overview
11.12.2 Financial Performance
11.12.3 Product Outlook
11.12.4 Key Development

11.13 CerCell
11.13.1 Overview
11.13.2 Financial Performance
11.13.3 Product Outlook
11.13.4 Key Development

11.14 Eppendorf
11.14.1 Overview
11.14.2 Financial Performance
11.14.3 Product Outlook
11.14.4 Key Development

11.15 Solaris Biotech Solutions
11.15.1 Overview
11.15.2 Financial Performance
11.15.3 Product Outlook
11.15.4 Key Development

12 Appendix
12.1 Related Reports